Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients. Methods: We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment. Results: We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all P≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, P<0.0001). Conclusions: IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.
Abstract
Background/Aims: Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients. Methods: We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment. Results: We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all P≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, P<0.0001). Conclusions: IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.
참고문헌 (47)
- Akinyemiju T, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : Results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- Polaris Observatory Collaborators, "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016 : a modelling study", Lancet Gastroenterol Hepatol, 3, pp.383~403 (2018)
- Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Chan AW, "Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B", J Gastroenterol Hepatol, 32, pp.667~676 (2017)
- Yun Bin Lee, "Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B", Clinical and Molecular Hepatology, 25(1), pp.52~64 (2019), 대한간학회
- Peleg N, "Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load", JHEP Rep, 1, pp.9~16 (2019)
- Choi HSJ, "Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B", Hepatology, 71, pp.539~548 (2020)
- Lim CT, "Presence of hepatic steatosis does not increase the risk of hepatocellular carcinoma in patients with chronic hepatitis B over long follow-up", Microbiol Insights (2020)[DOI]
- Mak LY, "Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection", Hepatol Int, 15, pp.901~911 (2021)
- Con D, "Epidemiology and outcomes of a chronic hepatitis B cohort with concurrent nonalcoholic fatty liver disease", Journal of Gastroenterology and Hepatology (Australia), 35(Suppl 1), pp.80~81 (2020)
- Li J, "Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B", J Infect Dis, 224, pp.294~302 (2021)
- David Sooik Kim, "Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir", Clinical and Molecular Hepatology, 25(3), pp.283~293 (2019), 대한간학회
- Wong GL, "Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations", Aliment Pharmacol Ther, 39, pp.883~893 (2014)
- Wong SW, "Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B", J Viral Hepat, 27, pp.1297~1305 (2020)
- Chen Y, "Effect of hepatic steatosis on the progression of chronic hepatitis B : A prospective cohort and in vitro study", Oncotarget, 8, pp.58601~58610 (2017)
- van Kleef LA, "Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B", JHEP Rep, 3, pp.100350~ (2021)
- Ieluzzi D, "Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy", Dig Liver Dis, 46, pp.427~432 (2014)
- Kim MN, "Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver", Aliment Pharmacol Ther, 55, pp.97~107 (2022)
- Bacaksız F, "Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients", Int J Clin Pract, 75, pp.e14899~ (2021)
- Chang JW, "No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B", J Viral Hepat, 28, pp.1545~1553 (2021)
- Chu CM, "Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without", Dig Dis Sci, 58, pp.275~281 (2013)
- Mak LY, "Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B", J Hepatol, 73, pp.800~806 (2020)
- Gong L, "Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B", Transplant Proc, 47, pp.2886~2891 (2015)
- Yu MW, "Hepatic steatosis and development of type 2 diabetes : Impact of chronic hepatitis B and viral specific factors", J Formos Med Assoc, 121, pp.1478~1487 (2022)
- Khalili M, "Hepatic steatosis and steatohepatitis in a large North American cohort of adults with chronic hepatitis B", Am J Gastroenterol, 116, pp.1686~1697 (2021)
- Hu D, "Nonalcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model", Hepatol Int, 12, pp.438~446 (2018)
- Feldstein AE, "Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis", Gastroenterology, 125, pp.437~443 (2003)
- Machado MV, "Hepatic steatosis in hepatitis B virus infected patients : meta-analysis of risk factors and comparison with hepatitis C infected patients", J Gastroenterol Hepatol, 26, pp.1361~1367 (2011)
- Stewart LA, "To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data", Eval Health Prof, 25, pp.76~97 (2002)
- Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- Stroup DF, "Meta-analysis of observational studies in epidemiology : a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology(MOOSE)group", JAMA, 283, pp.2008~2012 (2000)
- Wells GA, "The Newcastle-Ottawa Scale(NOS)for assessing the quality of nonrandomized studies in meta-analyses", Appl Eng Agric, 18, pp.727~734 (2014)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Le MH, "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States", PLoS One, 12, pp.e0173499~ (2017)
- Liu J, "Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance : a community-based follow-up study", Gastroenterology, 139, pp.474~482 (2010)
- McMahon BJ, "Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus", Ann Intern Med, 135, pp.759~768 (2001)
- Yeo YH, "Incidence, factors, and patient-level data for spontaneous HBsAg seroclearance : A cohort study of 11, 264 patients", Clin Transl Gastroenterol, 11, pp.e00196~ (2020)
- Mao X, "Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance : A systematic review and meta-analysis", Hepatology, 77, pp.1735~1745 (2023)
- Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions", pp.143~176 (2019), John Wiley & Sons
- Cho H, "Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B", J Clin Gastroenterol, 54, pp.633~641 (2020)
- 이재민, "Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B", Clinical and Molecular Hepatology, 22(3), pp.339~349 (2016), 대한간학회
- Lee M, "Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment", Hepatology, 66, pp.1556~1569 (2017)
- Wu LL, "Liver fibrosis is associated with NAFLD activity score in chronic hepatitis B patients with liver steatosis", Hepat Mon, 18, pp.e84182~ (2018)
- Charatcharoenwitthaya P, "The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response", Liver Int, 37, pp.542~551 (2017)
- Zhang RN, "Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response", Hepat Mon, 15, pp.e27909~ (2015)
- Seto WK, "A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance", Hepatology, 56, pp.812~819 (2012)